Avalo Therapeutics, Inc.
AVTXNASDAQHealthcare● Active
$12.74
$-0.36(-2.75%)
Market Cap$143887051
P/E Ratio—
52W High$24.27
52W Low$4.06
Avalo Therapeutics, Inc. (AVTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AVTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.98
Est. -$1.00 · +2.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
AVTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.63 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$1.00 | -$0.98 | +2.0% | — | — | — |
| ▲ Q1 FY2026 | Mar 23, 2026 | -$1.54 | -$0.37 | +76.0% | $0.00B | $0.00B | +34.8% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$1.67 | -$2.19 | -31.1% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$1.43 | -$1.92 | -34.3% | — | — | — |
| ▼ Q2 FY2025 | May 12, 2025 | -$1.07 | -$1.25 | -16.8% | — | — | — |
| ▼ Q2 FY2025 | Apr 4, 2025 | $0.58 | -$7.95 | -1470.7% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$1.19 | -$2.83 | -137.8% | $0.00B | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.63
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.98
EPS Est.
-$1.00
EPS Surpr.
+2.0%
Revenue
—
Q1 FY2026
Mar 23, 2026Beat
EPS Actual
-$0.37
EPS Est.
-$1.54
EPS Surpr.
+76.0%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$2.19
EPS Est.
-$1.67
EPS Surpr.
-31.1%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$1.92
EPS Est.
-$1.43
EPS Surpr.
-34.3%
Revenue
—
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$1.25
EPS Est.
-$1.07
EPS Surpr.
-16.8%
Revenue
—
Q2 FY2025
Apr 4, 2025Miss
EPS Actual
-$7.95
EPS Est.
$0.58
EPS Surpr.
-1470.7%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$2.83
EPS Est.
-$1.19
EPS Surpr.
-137.8%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.81 | $-0.81 | $-0.81 | 2 |
| Q3 FY2027 | $-0.67 | $-0.67 | $-0.67 | 2 |
| Q2 FY2027 | $-0.60 | $-0.60 | $-0.60 | 2 |
| Q1 FY2027 | $-0.53 | $-0.53 | $-0.53 | 2 |
| Q4 FY2026 | $-0.65 | $-0.65 | $-0.65 | 4 |
| Q3 FY2026 | $-0.76 | $-0.54 | $-0.33 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +2.0% | $19.94 | $19.85 | -0.45% |
| ▲ Q1 FY2026 | Mar 23, 2026 | +76.0% | $13.42 | $13.50 | +0.60% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -31.1% | $16.45 | $15.42 | -6.26% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -34.3% | $8.31 | $8.35 | +0.48% |
| ▼ Q2 FY2025 | May 12, 2025 | -16.8% | $4.06 | $4.00 | -1.48% |
| ▼ Q2 FY2025 | Apr 4, 2025 | -1470.7% | $6.59 | $5.80 | -11.99% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -137.8% | $13.40 | $12.91 | -3.66% |
| ▼ Q3 FY2024 | Aug 12, 2024 | -110.0% | $10.68 | $9.90 | -7.30% |
Q2 FY2026-0.45%
Report Date
May 13, 2026
EPS Beat/Miss
+2.0%
Price Before
$19.94
Price After
$19.85
Q1 FY2026+0.60%
Report Date
Mar 23, 2026
EPS Beat/Miss
+76.0%
Price Before
$13.42
Price After
$13.50
Q4 FY2025-6.26%
Report Date
Nov 6, 2025
EPS Beat/Miss
-31.1%
Price Before
$16.45
Price After
$15.42
Q3 FY2025+0.48%
Report Date
Aug 7, 2025
EPS Beat/Miss
-34.3%
Price Before
$8.31
Price After
$8.35
Q2 FY2025-1.48%
Report Date
May 12, 2025
EPS Beat/Miss
-16.8%
Price Before
$4.06
Price After
$4.00
Q2 FY2025-11.99%
Report Date
Apr 4, 2025
EPS Beat/Miss
-1470.7%
Price Before
$6.59
Price After
$5.80
Q4 FY2024-3.66%
Report Date
Nov 7, 2024
EPS Beat/Miss
-137.8%
Price Before
$13.40
Price After
$12.91
Q3 FY2024-7.30%
Report Date
Aug 12, 2024
EPS Beat/Miss
-110.0%
Price Before
$10.68
Price After
$9.90
Avg Beat Reaction+0.07%
Avg Miss Reaction-5.04%
Beat Rate2 / 8 quarters
Largest Move-11.99% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AVTX ends December
Avalo Therapeutics, Inc. (AVTX) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.98 — beating the analyst consensus of $-1.00 by +2.0%. AVTX has beaten EPS estimates for 2 consecutive quarters. The next AVTX earnings date is expected around September 1, 2026.
Each quarter, investors track AVTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AVTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AVTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AVTX earnings · 5 questionsAvalo Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. AVTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AVTX historically reports after market close (AMC).
AVTX earnings datewhen is AVTX earningsAVTX next earnings datewhen does AVTX report earningsAVTX earnings calendar
▸ Source: FMP · Avalo Therapeutics, Inc. SEC filings · US GAAP · Avalo Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026